Goldman Sachs Reiterates Conviction Buy on Quest Diagnostics (DGX)
Get Alerts DGX Hot Sheet
Rating Summary:
10 Buy, 20 Hold, 2 Sell
Rating Trend: Up
Today's Overall Ratings:
Up: 11 | Down: 12 | New: 9
Join SI Premium – FREE
Goldman Sachs reiterated its Conviction Buy rating on Quest Diagnostics (NYSE: DGX) and price target of $79.00.
Analyst Isaac Ro commented, "We reiterate our CL-Buy on Quest Diagnostics (DGX) heading into 2015. Labs and Services was the worstperforming coverage group in our Goldman Sachs Americas Healthcare coverage in 2014. While we acknowledge utilization trends have only recently signaled an improvement, we believe this underperformance sets up well for 2015 as cyclical and secular tailwinds emerge. Below we re-highlight the primary drivers of our Buy thesis."
For an analyst ratings summary and ratings history on Quest Diagnostics click here. For more ratings news on Quest Diagnostics click here.
Shares of Quest Diagnostics closed at $63.78 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Quest Diagnostics (DGX) PT Raised to $155 at Mizuho
- Acrivon Therapeutics Inc (ACRV) PT Lowered to $22 at Jones Trading
- Rubrik, Inc. (RBRK) IPO Opens at $38.60, Priced at $32
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Goldman Sachs Conviction Buy List, Goldman SachsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!